BLyS / TNFSF13B Protein (BAFF, CD257 Protein)
B-Lymphocyte Stimulator / Tumor Necrosis Factor (ligand) Superfamily, member 13B (B-cell Activating Factor, Cluster of Differentiation 257)
BLyS / TNFSF13B Products
BLyS / TNFSF13B Protein, Recombinant
10056-H01H: The EC50 of human TNFRSF17 is 0.07 µg/mL. Measured by its binding ability in a functional ELISA Immobilized recombinant human BAFF at 1 µg/mL (100 µl/well) can bind human TNFRSF17.
10056-HNCH: The ED50 for this effect is typically 0.4-2 ng/mL in the presence of goat anti-mouse IgM µ chain. Measured in a cell proliferation assay using antiIgM stimulated mouse B cells.
BLyS / TNFSF13B Antibody
||Description //For Detailed Info. and Price------CLICK!
||BAFF / TNFSF13B Antibody
BLyS / TNFSF13B Cell Lysates
BLyS / TNFSF13B cDNA Clone
BLyS / TNFSF13B Related Areas
Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>BLyS/TNFSF13B/CD257
Immunology>>Cytokine & Receptor>>TNF Superfamily>>BLyS/TNFSF13B/CD257
Immunology>>Cluster of Differentiation>>Dendritic Cell CD Antigen>>Dendritic Cell Co-stimulatory Molecules>>BLyS/TNFSF13B/CD257
Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Other>>BLyS/TNFSF13B/CD257
Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>Helper T Cells>>BLyS/TNFSF13B/CD257
BLyS / TNFSF13B Alternative Names
BLYS, TNFSF13B, BAFF, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, ZTNF4 [Homo sapiens]
BlyS, Tnfsf13b, BAFF, D8Ertd387e, MGC124060, MGC124061, TALL-1, TALL1, THANK, TNFSF20, zTNF4 [Mus musculus]
BLyS / TNFSF13B Background
B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
BLyS / TNFSF13B Related Studies
- Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
- Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
- Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
TNF Superfamily Ligands
TNF Receptor Superfamily